Physician profile
Patrick Ivar Erickson
NPI 1588105415
$7,482.61
in general payments reported to CMS, 2019-2025
50 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.15 · 2022: $467 · 2023: $1,918 · 2024: $2,307 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,931 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,930.78 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,063.18 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $614.77 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $542.06 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $492.75 | 2022-2025 | |
| Lilly USA, LLC | $485.57 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $481.52 | 2024-2025 | Zenpep, Vowst |
| Exact Sciences Corporation | $334.90 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.23 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $219.83 | 2023-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $178.64 | 2024-2025 | Qelbree, Xyosted |
| E.R. Squibb & Sons, L.L.C. | $175.82 | 2022-2025 | Eliquis, Cobenfy, Camzyos |
| Astellas Pharma US INC | $129.73 | 2023-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $129.12 | 2022-2025 | Austedo Xr |
| Pfizer INC. | $104.64 | 2023-2025 | |
| Edwards Lifesciences Corporation | $87.27 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $82.83 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $78.68 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $76.89 | 2023-2024 | Spravato |
| Glaxosmithkline, LLC. | $75.60 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Corcept Therapeutics | $67.56 | 2023-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.08 | 2025 | Xifaxan |
| Lundbeck LLC | $48.80 | 2024-2025 | Rexulti |
| Abbott Laboratories | $47.60 | 2025 | Freestyle Libre 3 |
| Halozyme INC | $44.23 | 2023 | |
| Ironshore Pharmaceuticals INC. | $39.28 | 2022-2023 | Jornay Pm |
| Vertex Pharmaceuticals Incorporated | $36.40 | 2024-2025 | |
| Corium, LLC | $36.19 | 2023-2024 | Azstarys |
| Antares Pharma, INC. | $33.73 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Phathom Pharmaceuticals, INC. | $32.93 | 2025 | Voquezna |
| Harmony Biosciences LLC | $29.62 | 2023 | Wakix |
| Amgen INC. | $29.40 | 2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $29.37 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $29.27 | 2022-2025 | Zoryve |
| Inspire Medical Systems, INC. | $26.46 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $25.80 | 2023 | Sunosi |
| Vanda Pharmaceuticals INC. | $24.90 | 2025 | Fanapt |
| Arbor Pharmaceuticals, INC. | $24.80 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.55 | 2023 | Strensiq |
| Neuronetics, INC. | $21.43 | 2025 | Neurostar Tms Therapy System |
| Organon LLC | $20.89 | 2024 | |
| Grifols USA, LLC | $20.71 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.85 | 2024 | Trintellix |
| Medtronic, INC. | $17.12 | 2023 | Venaseal |
| Idorsia Pharmaceuticals US INC | $17.11 | 2025 | Quviviq |
| Gilead Sciences, INC. | $16.60 | 2025 | |
| Merck Sharp & Dohme LLC | $16.39 | 2024 | Vaxelis, Vaxneuvance, Gardasil |
| Exeltis, USA INC. | $13.92 | 2025 | Slynd |
| Alkermes, INC. | $13.90 | 2023 | Lybalvi |
| Seqirus USA INC | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.